SEARCH:
Print

Board of Directors

Gerard van Odijk, MD

Gerard van Odijk, MD

Member of the board since 2008 and chairman since 2014. Not independent. Chairman of the Nomination and Compensation Committee since 2015 and member of the Science Technology & Investment Committee since 2020. Current term expires in 2021

Dr. van Odijk is a Dutch national, born in 1957.

Former president and chief executive officer of Teva Pharmaceuticals Europe B.V.

Current positions: Chairman of the supervisory board of Hubrecht Organoid Technology. Member of the supervisory board of Centre for Human Drug Research.

Special competences: Medical qualifications and extensive executive background within publicly traded and private companies in the international healthcare industry.

Anders Gersel Pedersen, MD, PhD

Anders Gersel Pedersen, MD, PhD

Member of the board since 2010 and deputy chairman since 2014. Independent. Member of the Nomination and Compensation Committee and the Science Technology & Investment Committee since 2020. Current term expires in 2021.

Dr. Pedersen is a Danish national, born in 1951.

Former Executive Vice President of Research & Development of H. Lundbeck A/S.

Current positions: Member of the board of Genmab A/S, Hansa Biopharma AB and Bond Avillion 2, an entity of Avillion LLP. Chairman of the board of Aelis Farma.

Special competences: Scientific knowledge and large drug development experience within neuroscience and oncology. Extensive board and management experience from publicly traded, international pharmaceutical and biotech companies.

Erik G. Hansen, MSc

Erik G. Hansen, MSc

Member of the board since 2010. Independent. Member of the Finance, Risk and Audit Committee and the Science Technology & Investment Committee since 2020. Current term expires in 2021.

Mr. Hansen is a Danish national, born in 1952.

Professional board member.

Current positions: Chairman of the board of Polaris Management A/S, TTiT A/S, TTiT Ejendomme A/S, TTiT Landbrug A/S and Sirius Holding ApS. Deputy chairman of the board of Lauritzen Fonden, Okono A/S, Bagger-Sørensen Fonden and Bagger-Sørensen & Co. A/S and four of its five subsidiaries. Member of the board of Saga Private Equity ApS, Lesanco ApS, Ecco Sko A/S, Farumgade 2B Holding ApS and its subsidiary and Wide Invest ApS. Member of the executive board of Rigas Holding ApS and its 3 subsidiaries, Sirius Holding ApS, Tresor Asset Advisers ApS, Polaris Invest II ApS and EGH Gentofte ApS.

Special competences: Training and experience in and thorough understanding of managing finance operations and experience with publicly traded companies.

Peter Kürstein, MBA

Peter Kürstein, MBA

Member of the board since 2012. Independent. Member of the Nomination and Compensation Committee since 2015 and the Finance, Risk and Audit Committee since 2020. Current term expires in 2021.

Mr. Kürstein is a Danish national, born in 1956.

Former president and chief executive officer of Radiometer Medical ApS.

Current positions: Chairman of the board of Radiometer Medical ApS and Ferrosan Medical Devices Holding A/S. Deputy Chairman of the board of FOSS A/S, Experimentarium and American Chamber of Commerce. Member of the board of N. Foss & Co. A/S and Den Erhvervsdrivende Fond Gl. Strand, Dansk BørneAstma Center and Art Agenda 2030. Member of the executive board of Mijamax ApS.

Special competences: Extensive board and management experience from publicly traded, international healthcare companies.

Frank Verwiel, MD

Frank Verwiel, MD

Member of the board since 2016. Independent. Member of the Finance, Risk and Audit Committee since 2016 and the Nomination and Compensation Committee since 2020. Current term expires in 2021.

Dr. Verwiel is a Dutch national, now resident of the USA, born in 1962.

Former president and chief executive officer of Aptalis Pharma, Inc.

Current positions: Chairman of the board of ObsEva SA and member of the board of Intellia Therapeutics, Inc.

Special competences: Extensive strategic, operational and international experience within the pharmaceutical industry.

Elizabeth McKee Anderson, MBA

Elizabeth McKee Anderson, MBA

Member of the board since 2017. Independent. Chairman of the Science Technology & Investment Committee since 2020. Current term expires in 2021.

Ms. Anderson is an American national, born in 1957.

Former worldwide vice president, Global Strategic Marketing and Market Access, Infectious Diseases and Vaccines for Johnson&Johnson.

Current positions: Member of the board of Revolution Medicines Inc., BioMarin Pharmaceutical Inc., Insmed Inc., Aro Biotherapeutics Company and a member of the advisory Board of NAXION, Inc. Trustee of The Wistar Institute and principal of Pure-Sight Advisory, LLC.

Special competences: Extensive strategic, operational and international experience within the pharmaceutical industry.

Anne Louise Eberhard, MSc Law

Anne Louise Eberhard, MSc Law

Member of the board since 2019. Independent. Chairman of the Finance, Risk and Audit Committee since 2020. Current term expires in 2021.

Ms. Eberhard is a Danish national, born in 1963.

Former Senior Executive Vice President of Danske Bank A/S.

Current positions: Member of the board of FLSmidth & Co. A/S and its subsidiary FLSmidth A/S, Topdanmark A/S and its subsidiary Topdanmark Forsikring A/S, Knud Højgaards Fond and two of its three subsidiaries and VL 52 ApS. Chairman of the board of Moneyflow Group A/S and its subsidiary Moneyflow 1 A/S. Deputy Chairman of the board of Finansiel Stabilitet SOV. CEO of EA Advice ApS. Faculty Member at Copenhagen Business School, Board Educations.

Special competences: Extensive finance and risk management experience as well as board experience from publicly listed companies.